ArticleFrontiers in pharmacology2026

Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysis.

Ling Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.